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Abstract
Background: The number of individuals at risk for dementia will probably increase in ageing
societies as will the array of preventive and therapeutic options, both however within limited
economic resources. For economic and medical purposes valid instruments are required to assess
disease processes and the efficacy of therapeutic interventions for different forms and stages of
illness. In principal, the impact of illness and success of an intervention can be assessed with
biomedical variables, e.g. severity of symptoms or frequency of complications of a disease.
However, this does not allow clear judgement on clinical relevance or comparison across different
diseases.
Discussion: Outcome model variables such as quality of life (QoL) or health care resource
utilization require the patient to appraise their own well-being or third parties to set preferences.
In Alzheimer's disease and other dementias the evaluation process performed by the patient is
subject to the disease process itself because over progress of the disease neuroanatomical
structures are affected that mediate evaluation processes.
Summary: Published research and methodological considerations thus lead to the conclusion that
current QoL-instruments, which have been useful in other contexts, are ill-suited and insufficiently
validated to play a major role in dementia research, decision making and resource allocation. New
models integrating biomedical and outcome variables need to be developed in order to meet the
upcoming medical and economic challenges.
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Background
Prevalence of Alzheimer's disease and other dementias
increase in the aging societies of the Western hemisphere.
This puts an ever increasing burden on the health care sys-
tems. Considering increasing treatment options over
almost the whole spectrum of diseases effective spending
of the resources of health care systems is warranted to pro-
vide a fair if not comprehensive care. Hence payers, physi-
cians and patients will need to weigh costs and benefits of
future interventions much more carefully. The "burden of
illness" and "quality of life" convey greater meaning and
more direct relevance across a wide spectrum of diseases
and illnesses than abstract clinical or scientific parame-
ters, and such dimensions will gain greater appeal for a
larger community involved in future decisions.
Biomedical measures are appropriate to determine the
consequences of disease on specific medically relevant
symptoms. For oncological diseases this may include the
size of the tumor or the number and region of metastases.
In order to assess the impact on the patient's everyday life
these biomedical measures need to be supplemented by
other measures relating to everyday life such as the quality
of life or pain. For dementing disorders specific symptoms
of disease such as cerebral atrophy can be measured in
much the same way as the size of a tumor. Beyond this,
several symptoms of dementia, e.g. the impairment of
memory, can be measured with standardized instruments,
whose relevance for everyday life is obvious. Over the
course of Alzheimer's dementia the burden of disease is
not primarily reflected by diminishing cognitive functions
of patients, but also by a variety of behavioural problems
and physical handicaps. There is, however, a great deal of
heterogeneity regarding the manifestation of, and the cop-
ing with these non-cognitive symptoms. Therefore more
comprehensive instruments are required to take account
of such causes and their effects within the context of fam-
ily or professional care.
Quality of Life (QoL) measurements require the patient's
self-assessment of his or her fulfilment and impairment in
everyday life. Sometimes seemingly negligible causes lead
to major handicaps, and severe changes regarding the
quality of life and resource usage, whereas severe medical
problems need not be associated with apparent subjective
consequences. These observations suggest that data on
subjective relevance and economic outcomes should be
included in clinical studies in order to prepare the ground
for future cost-effectiveness models which will need to
include the subjective and social impact of illness and
interventions. [1].
We will address several moot points regarding the use of
"quality of life" and other concepts and instruments,
which have been developed for other target groups, but
are now employed in the context of dementia. We hope to
prevent premature conclusions based on the uncritical
administration of such scales in patients with dementia,
and we argue for the development of adequate tools.
Discussion
Biomedical instruments for assessing dementia
Dementia is a frequent disorder in the elderly and its prev-
alence increases with age [2]. The most frequent cause is
AD. At onset of AD the medial temporal lobe is affected
[3] resulting in episodic memory deficit as the early clini-
cal hallmark [4]. As the disease spreads, other brain
regions are affected as well. The parietal cortex mediates
functions such as spatial orientation and visuospatial
functions [5,6], the frontal cortex executive functions,
planning, attention, and working memory [7-9]. Spread
of AD beyond the temporal lobe thus is characterized in
functional terms by accruing deficits of spatial orienta-
tion, attention and executive functions as well as working
memory and language [4] beyond initial temporal lobe
type memory deficits. This can be visualized using
advanced imaging methods [10,11].
For Clinical Study purposes test batteries are used, most
commonly the Mini Mental Status Examination (MMSE)
[12,13] and the Alzheimer's Disease Assessment Scale
(ADAScog). Cognitive scales such as the MMSE or the cog-
nitive sub-scale of the ADAScog mingle the results of sev-
eral cognitive functions into one composite score. While
any of the assessed symptoms might be present at one
time point or the other during the course of an individ-
ual's disease they will not be present all at once at any
given stage of disease. Moreover, the dynamic range for
observation of change is not the whole band of the scale
but a small margin centered around the observed score.
Unfortunately, the sensitivity to change of these scores is
not linear over the course of disease. As recently reviewed
[14] it often is argued that a certain score difference, e.g. a
4-point difference in the ADAScog score, represents a
meaningful clinical outcome. However, this judgement
remains arbitrary and does not reflect clinical observa-
tions of large score differences with hardly any differences
in everyday life and vice versa.
Impact of disease in terms of Quality of Life (QoL)
The concept of QoL relates to the 1947 definition of
'health' by the World Health Organization (WHO) as
being a state of complete physical, mental, and social
well-being [15]. In a similar fashion, Lawton character-
ized five domains pertaining to QoL for subjects with
dementing illnesses to comprise the same areas as in peo-
ple in general (cognitive functioning, ability to perform
activities of daily living, being able to engage in meaning-
ful time use, social behavior, as well as a favorable balance
between positive emotion and absence of negative emo-BMC Neurology 2009, 9:47 http://www.biomedcentral.com/1471-2377/9/47
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tion) [16]. As QoL refers to all aspects of a patient's life, it
can provide complementary and valuable information on
the patient's self perception of health and treatment
impact. Therefore, QoL is suggested in many disease areas
as an important outcome to evaluate new treatments.
Considering the subjective nature of the QoL concept it is
generally agreed that any appraisal thereof at best should
rely on the perception of the individual to be looked at.
The use of proxies (e.g relatives or a nurse) to measure
QoL has inherent obstacles, such as personality character-
istics of the proxy, the nature of the relationship, the time
spent with one another, and the level of impairment. Fre-
quently, proxy appraisal of the patient's QoL are disparate
to the patients own evaluation [17]. Moreover, discrepan-
cies between dementia patients' and their caregivers' rat-
ings of the patients' quality of life are associated with
increased levels of caregiver burden, rather than lower lev-
els of patients' functioning alone [18,19] and thus are not
only related to the disease process in the patient but exter-
nal and internal factors of the proxy. The proxie's experi-
ences of depression and burden might also negatively
affect proxies' assessments of QoL [17]. Despite these
observations this procedure has been used when patients
are too severely impaired to complete the rating them-
selves. At best, proxy-ratings can be considered as comple-
mentary information for self-ratings but not as a
substitute. Despite these difficulties and need for further
methodological research [20], QoL has become an impor-
tant dimension of AD therapeutic research [21] and
health economic analyses in this area.
There are different concepts to measure a health-related
quality of life (QoL). Rather than qualifying the
approaches purely as either medical or economic, a meth-
odological classification would focus on the major com-
ponents used in describing and valuating QoL of
dementia patients (Table 1). For measuring QoL of those
who provide care for dementia patients (e.g., relatives)
Table 1 without the proxy category would most likely be
adequate. All approaches to value QoL require a descrip-
tive element. (The literature mentions valuations based
on numerical ratings alone, however, without a descrip-
tive basis their valuation lacks any relation to aspects of
the health status).
Quality of Life – Utility Measure in Health Economics
In economic cost-utility studies generic descriptions of
QoL are combined with preference-based valuations.
From an economic perspective, the preferences of the
individual are the key criteria to assess whether goods or
services can be considered "efficient"' from the perspective
of the consumer (for most consumers, even the most cost-
effectively produced shoes would be worth little if it were
only left ones). Economists would suggest eliciting the
preferences of those individuals affected by an interven-
tion. When looking from a medical point of view, this
would definitely be the patient. As in dementia the choice
of the approach may be restricted by the capabilities of the
patient, one would have to consider surveying a proxy
(e.g., a relative) instead of the patient in cases where he
would be unable to articulate his preferences but the use
of this approach may be limited (cf. above).
Yet there are also other positions in the discussion with
respect to the preferences to be used for valuation. When
the question is about which services are to be covered in a
national or statutory health service, some economists
argue that it is the general population which is affected
and that, accordingly, their preferences should be used for
valuation (which is then typically derived via given pre-
defined standardized health states in interviews or sur-
veys). This approach, however, is distorted given the lack
of knowledge about Alzheimer's disease in the general
population [22-25]. The key problem in valuation, in any
case, is to give a summary statement on QoL that inte-
grates all different aspects of health at stake. Any answer
to this problem should be scientifically well motivated. A
simple solution is to use a pre-defined algorithm instead
of preferences, e.g. a sum score across a health profile. Yet,
Table 1: Classification of approaches to describe and valuate QoL according to the person surveyed
Person surveyed or person defining Measures to describe QoL Procedures to valuate QoL
Generic Disease-specific Externally defined a Preference-based b
Patient I II - 1
Proxy III IV - 2
Scientist -- 3 -
Population -- - 4
a e.g. a sum score
b especially according to the procedures of VAS, TTO and SG, enabling the calculation of QALYsBMC Neurology 2009, 9:47 http://www.biomedcentral.com/1471-2377/9/47
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this might only reflect the judgement of the constructor of
the sum score. Obviously, constructors, the general popu-
lation, the proxy or the patient himself may not assess a
health state, such as e.g. mild dementia, in the same way.
In the end, the choice of the method to integrate all health
aspects will also depend on the type of decision that waits
to be supported by the QoL data but proceeding in such a
way somewhat forecloses a later result. Furthermore, the
methodological usefulness of the approach used to
describe and valuate QoL must be critically considered.
The most important criteria for psychometric testing
include reliability, validity and responsiveness [26]. For
any measurement of QoL that claims to rely on scientific
grounds it is necessary to show that the instrument used is
psychometrically appropriate for the target group of
patients or population analyzed – the foundation of what
is being measured, and how well this is being achieved, is
lacking otherwise. Accordingly, respective methodologi-
cal pilot studies are required as long as the respective
properties of the measurement instrument cannot be
quoted from the literature.
In clinical research, one of the important differences of
different QoL measures is measuring health status or util-
ity of different health states. Health status measures
describe functioning and the impact of illness on health.
They are generally subdivided into generic and disease-
specific measures. The generic measures are intended for
general use and suitable for wide range of patient groups.
Measuring general health status is important because it
shows the extent to which interventions really make a dif-
ference to a patient's overall life and helps to quantify the
relative effects of different interventions for patients with
different diseases. The SF-36 and the EQ-5D instruments
are the most frequently used generic QoL measures world-
wide, while only for the EQ 5D broadly acknowledged
valuation procedures are available to elicitate correspond-
ing utilities. Typically one of these generic measures in
clinical research is combined with one or more disease-
specific measures. The latter aim at emphasizing problems
specific to patients with the disease in question (e.g.
EORTC QLQ-C30 or FACT-G in cancer research or the
QOL-AD focusing on Alzheimer's disease). Compared
with generic measures, disease-specific measures nor-
mally are more sensitive and responsive to the changes in
the assessment of QoL of specific patient groups.
Utilities measures describe utilities or quality-of-life
weights to health states derived by either direct or indirect
utility measures. Direct utility measures include visual
analogue scales (VAS), standard gamble (SG), and time
trade-off (TTO) techniques. VAS asks patients to indicate
on an e.g. 10 cm Likert scale the position of their current
state, and also to mark positions corresponding to various
scenarios. SG attempts to estimate patient's preferences
under uncertainty, where the uncertainty involves a risk of
death or some other outcome. On the other hand, TTO
measures patients' preferences under certainty. The
patients are asked to indicate whether they would choose
one year in perfect health or one year with impaired
health. SG and TTO have been found to be practical on
most populations with TTO being a commonly used sub-
stitute for the SG method and vice versa. Some QoL
instruments were developed to produce a series of health
utilities, such as the Quality of Well-Being scale (QWB),
the Health Utilities Index (HUI) and the EQ-5D from the
EuroQoL group. They are referred to as being generic or
indirect utility measures and in practice the generic utility
measures are widely used mainly due to their ease in use:
The answers of only few questions result in a QoL-utility.
For example using the EQ-5D patients have to answer five
questions, one question for one dimension of QoL
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression), and give an expression of their cur-
rent state of QoL via the VAS.
These utility measures assign values or utilities for health
states from 0.0 to 1.0, where 0 is defined as death and 1 is
defined as the best possible health state. The health state
utilities are used to calculate quality-adjusted life-years
(QALYs) which are applied in cost-utility or cost-effective-
ness analysis. Based on health-related quality of life and
survival for the patient, QALYs can assess the extent of the
benefits gained from interventions. During that approach
not only gained life time but also quality of that time
gained is combined and it is defined that there exists the
possibility of trade off between these two aspects. When
the QALY is used in different indications and/or interven-
tions, cross-comparisons can be made to describe the rel-
ative benefit for patients. When combined with the costs
of providing the interventions, decision makers can
understand the relative cost-effectiveness of different
interventions. When resources are scarce one can argue
that those interventions should be reimbursed which pro-
vide the best incremental cost-effectiveness ratio.
Regardless of whether a method is used that asks for a
direct appraisal by the patient or that assesses of prefer-
ences these approaches implicitly assume that the patient
is in a position to perform a valid appraisal of his or her
own situation and that a sufficient knowledge about the
disease is at hand.
Deficits of judgement and decision-making in patients with 
dementia
Competent choices require awareness of competences and
restrictions and a deliberate judgement on well- or ill-
being despite present and future deficits. Lesions or mal-
functioning of the frontal and prefrontal cortex foster a
lack of awareness of deficits and impairments and ulti-
mately the inability of formulating a free will [27]. A
recent functional imaging study demonstrated this even inBMC Neurology 2009, 9:47 http://www.biomedcentral.com/1471-2377/9/47
Page 5 of 8
(page number not for citation purposes)
a semi-quantitative fashion. Decreased awareness was
positively correlated with perfusion deficits in frontal
regions [28]. It is unclear yet, whether impairment of def-
icit awareness is predominantly associated with frontal
cortex malfunction or overall severity of central nervous
system disease. While some studies suggest that the
former is true [29] other studies suggest the latter [30-33].
Impaired awareness of deficits has been associated with
malfunctions of the right hemisphere [34], the temporo-
parietal junction [35], the right prosubiculum of the hip-
pocampus [34], the parietal cortex [36], and the anterior
cingulate gyri [37]. Thus a widespread network is involved
in the awareness of deficits. This network is affected early
on during progressing AD or other dementias although
the pattern is unpredictable and subject to the specific dis-
ease and other internal and external factors in the patient,
e.g. comorbidities.
Patients with mild dementia [27,34,38-42] and even
those with Mild Cognitive Impairment (MCI) [43] fre-
quently demonstrate decreased awareness of their cogni-
tive impairments and change of behaviour. In particular,
decreased awareness of deficits manifests as poor aware-
ness of deficits in activities of daily living (ADL) [30].
Compared to their proxies, AD and MCI patients underes-
timate their deficits [36,44]. Moreover, however, family
informants may also fail to recognize memory problems
in subjects subsequently found to have dementia [45].
Patients' awareness of deficits is associated positively or
negatively with age, gender, pre-morbid education and
socioeconomic status in a complex fashion [31,46]. In
general, awareness of deficits seems to decrease with an
increased severity of dementia [30-32]. Awareness of def-
icits is modulated by even sub-syndromal depression,
anxiety, psychosis, and apathy [28,31,47]. This modula-
tion is subject to pre-morbid capacities as depressive
symptoms and awareness were found to be positively
related in high, but not low, cognitive reserve groups [48].
Standard approaches to judge the future impact of deficits
on subjective well-being are also impaired in AD. AD
patients perform less well in gambling tasks than elderly
controls and show impairments in cognitive estimation
[49]. Psychopharmacological and pathological evidence
supports the concept of a 'cholinergic component' of con-
scious awareness [50]. In AD, a cholinergic deficit has
been established many years ago [51] so that for this dis-
ease in particular the ability of the patient to undertake a
deliberate choice is questioned.
On these grounds it can be expected that patients with
mild AD have difficulties in taking decisions in every-day
life situations, both in cases of ambiguity (information on
probability is missing or conflicting, and the expected util-
ity of the different options is incalculable) and in cases of
risk (outcomes can be predicted by well-defined or esti-
mable probabilities) [52]. Moreover, AD patients fre-
quently change between strategies so that decisions are
given in a random fashion which precludes the develop-
ment of a consistent response pattern over time [53].
Where to go?
In a summary recommendation aiming at patients after
reviewing studies for dementia drugs, The American Col-
lege of Physicians & The American Academy of Family
Physicians concluded that outcomes related to QoL were
studied (and hence, captured) less frequently than other
outcome measures, and did not show consistent improve-
ments attributable to drugs analyzed. Considering that
dementia studies do not use survival as endpoint but
rather employ intermediate surrogate endpoints, this is a
remarkable statement. This enhances the need to elabo-
rate on difficulties in accurately measuring QoL for this
patient group [54]. Methodological problems are pin-
pointed when it comes to measuring the impact of drug
treatment on QoL of dementia patients in terms of QALYs
(Table 2).
A few key questions which type of studies might be able to
answer some questions appropriately can be taken from a
current British consensus paper on good health economic
modelling standards [55]: "Are the utilities incorporated
into the model weights (utilities) appropriate? Is the
source for the utility weights referenced? Are the methods
of derivation for the utility weights justified?"
In their health technology assessment report on dementia
drugs for the U.K. National Institute for Health and Clin-
Table 2: Appraisal of the internal validity of the QALY-endpoint in six cost-utility studies in the HTA on dementia drugs [56]
Product assessed (study) Internal validity Comment on generation of QALYs
Donepezil [58] Unacceptable Based on the Index of Health Related Quality of Life (IHQL) which was not 
validated for valuing cognitive impairment, and no rationale was given for the 
IHQL values used
Donepezil [59] Unclear or unknown Not stated
Rivastigmine [60] Unacceptable Based on the IHQL (see above)
Galantamine [61,62] Unclear or unknown Derived from [63] (pre – full time care at 0.60, full time care at 0.34)
Memantine [64] Unclear or unknown/unacceptable Insufficient detail found in the studyBMC Neurology 2009, 9:47 http://www.biomedcentral.com/1471-2377/9/47
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ical Excellence (NICE) Loveman et al [56] have evaluated
the use of the QALY-endpoint in six cost-utility studies.
Not one of the studies investigated achieved the label of
being internally valid at this point, some of them lacking
transparency, some lacking appropriate measurement
instruments, and others using too simple assumptions
(table 2). Next to the published literature, the industry
submissions on the drugs investigated in this study were
evaluated according to the quoted Philips et al. (2006)
standards [55] with respect to the utility measurement.
Again, no classification as 'internally valid' could be
achieved.
It can thus be concluded that large gaps exist between
published measurements of QoL in terms of utility and
the quality standards required by guidelines. This conclu-
sion is further supported by a consensus statement on
measuring treatment benefits in dementia, in which the
International Psychogeriatric Association has stated that
health utility measures are not validated satisfactorily in
dementia and that this calls into question previous health
economic analyses [57].
These sobering findings on QALY measurements in
dementia patients would further worsen if the guidelines'
requirements were extended for the above claimed need
to show the usefulness of the measurement instruments
used according to the usual psychometric testing criteria
which were not met by the quoted studies. Future
research, [56] concluded accordingly, should include
information on the quality of the outcome measures used
as well as the need to establish QoL instruments for
dementia patients.
Summary
We conclude that current outcome model variables, espe-
cially quality of life measures, are well suited and estab-
lished for non-dementing diseases but at present are not
fully suited to be rested upon in medical or health eco-
nomic analyses of disease impact or therapeutic interven-
tions in the dementias. The function of representation of
objective measures as obtained by biomedical assess-
ments or proxy measures in their relation to everyday life
or instruments of quality of life assessments is elusive, yet
(Figure 1). In consideration of the increasing prevalence
Measures relevant for dementias Figure 1
Measures relevant for dementias.BMC Neurology 2009, 9:47 http://www.biomedcentral.com/1471-2377/9/47
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of Alzheimer's disease and other dementias in old age an
integrative model of biomedical and outcome model var-
iables is warranted to face the upcoming medical and
health economic challenges.
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